Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Zhejiang University. Science. B ; (12): 355-362, 2019.
Artigo em Inglês | WPRIM | ID: wpr-1010466

RESUMO

OBJECTIVE@#This study demonstrated that dexamethasone (DEX) protects the endothelial glycocalyx from damage induced by the inflammatory stimulus tumor necrosis factor-α (TNF-α) during severe acute pancreatitis (SAP), and improves the renal microcirculation.@*METHODS@#Ninety mice were evenly divided into 3 groups (Sham, SAP, and SAP+DEX). The SAP mice model was established by ligature of pancreatic duct and intraperitoneal injection of cerulein. Renal perfusion and function, and morphological changes of the glycocalyx were evaluated by laser Doppler velocimetry, electron microscopy, and histopathology (hematoxylin and eosin (H&E) staining), respectively. Serum levels of syndecan-1 and TNF-α were assessed by enzyme-linked immunosorbent assay (ELISA). The protective effects of dexamethasone on the glycocalyx and renal microcirculation were evaluated.@*RESULTS@#Significantly high levels of serum TNF-α were detected 3 h after the onset of SAP. These levels might induce degradation of the glycocalyx and kidney hypoperfusion, resulting in kidney microcirculation dysfunction. The application of dexamethasone reduced the degradation of the glycocalyx and improved perfusion of kidney.@*CONCLUSIONS@#Dexamethasone protects the endothelial glycocalyx from inflammatory degradation possibly initiated by TNF-α during SAP. This is might be a significant discovery that helps to prevent tissue edema and hypoperfusion in the future.


Assuntos
Animais , Masculino , Camundongos , Doença Aguda , Dexametasona/farmacologia , Modelos Animais de Doenças , Edema/metabolismo , Endotélio Vascular/metabolismo , Ensaio de Imunoadsorção Enzimática , Glicocálix/efeitos dos fármacos , Rim/efeitos dos fármacos , Camundongos Endogâmicos C57BL , Microcirculação , Pancreatite/tratamento farmacológico , Perfusão , Substâncias Protetoras/farmacologia , Fator de Necrose Tumoral alfa/metabolismo
2.
Chinese journal of integrative medicine ; (12): 611-618, 2016.
Artigo em Inglês | WPRIM | ID: wpr-287174

RESUMO

<p><b>OBJECTIVE</b>To investigate the effect of Xuezhikang (, XZK) on renal cell apoptosis in diabetic rats and the possible mechanism.</p><p><b>METHODS</b>Sixty-six rats were randomly divided into 3 groups: the normal, model and XZK groups. In each group, the rats were further randomly divided into 3-month and 6-month subgroups, respectively. Diabetes of rats was induced by a single intraperitoneal injection of 1% streptozocin at 60 mg/kg body weight. Rats in the XZK group received gastric perfusion of XZK (1200 mg/kg body weight) everyday for 3 or 6 months, while rats in the normal and model groups received equal volume of saline. Twenty-four hours' urine was collected for urinary albumin excretion (UAE) measurement. Periodic acid-Schiff (PAS) and Masson's trichrome staining were used for saccharides and collagen detection. Cell apoptosis of renal cortex was investigated by TdT-mediated dUTP nick end labeling (TUNEL) staining. Bax and Bcl-2 expressions were detected by immunohistochemistry and Western blot, respectively. Cytochrome C (Cyt C) and caspase-9 concentration were detected by Western blot.</p><p><b>RESULTS</b>Compared with the model group, XZK treatment could significantly decrease the kidney hypertrophy index, 24 h UAE, renal cell apoptosis, cytoplasmic Cyt C level and active caspase-9 level, as well as suppress the increment of Bax and up-regulate the expression of Bcl-2, leading to the suppression of Bax/Bcl-2 ratio at 3 and 6 months (P<0.05 or P<0.01). Moreover, XZK treatment could alleviate the deposition of PAS-stained saccharides and Masson's trichromestained collagen to different extent.</p><p><b>CONCLUSIONS</b>Renal cell apoptosis was observed in diabetic kidney, in which mitochondrial apoptotic pathway might be involved. XZK treatment could attenuate pathological changes in diabetic kidney and reduce renal cell apoptosis, probably via the suppression of Bax/Bcl-2 ratio, which lead to inhibition of Cyt C release and following caspase-9 activation.</p>


Assuntos
Animais , Masculino , Albuminúria , Sangue , Apoptose , Glicemia , Metabolismo , Caspase 9 , Metabolismo , Citocromos c , Metabolismo , Diabetes Mellitus Experimental , Sangue , Tratamento Farmacológico , Metabolismo , Patologia , Medicamentos de Ervas Chinesas , Farmacologia , Usos Terapêuticos , Hipertrofia , Marcação In Situ das Extremidades Cortadas , Rim , Patologia , Glomérulos Renais , Patologia , Lipídeos , Sangue , Células Mesangiais , Patologia , Proteínas Proto-Oncogênicas c-bcl-2 , Metabolismo , Ratos Sprague-Dawley , Estreptozocina , Proteína X Associada a bcl-2 , Metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA